Paolo Macor
0000-0003-3079-4019
47 papers found
Refreshing results…
Complement as effector system in cancer immunotherapy
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats
Complement Activated by Chimeric Anti-Folate Receptor Antibodies Is an Efficient Effector System to Control Ovarian Carcinoma
Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59
The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: In vitro and in vivo studies
Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro.
Missing publications? Search for publications with a matching author name.